Skip to main content
. 2014 May 1;110(11):2655–2661. doi: 10.1038/bjc.2014.209

Figure 1.

Figure 1

(A) Plasma concentrations of TMZ following multiple doses of 75 mg m−2 of TMZ without (Day 7, Cycle 1) and after concomitant treatment (Day 21, Cycle 1) with multiple oral doses of 200 mg BID sorafenib in patients of cohort 2 (geometric means, geometric SD; n=6). (B) Plasma concentrations of AIC following multiple doses of 75 mg m−2 of TMZ without (Day 7, Cycle 1) and after concomitant treatment (Day 21, Cycle 1) with multiple oral doses of 200 mg BID sorafenib in patients of cohort 2 (geometric means, geometric SD; n=6).